Inhibition of BMP signaling suppresses metastasis in mammary cancer

Oncogene

Volumn 34, Issue 19, 2015, Pages 2437-2449

  Owens, P ^a   Pickup, M W ^a   Novitskiy, S V ^a   Giltnane, J M ^b   Gorska, A E ^a   Hopkins, C R ^b,c   Hong, C C ^b,d   Moses, H L ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d Department of Chemistry Vanderbilt University College of Arts and Science ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DMH1 COMPOUND; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; FEMALE; FIBROBLAST; HUMAN; LUNG NEOPLASMS; LYMPH VESSEL; MACROPHAGE; MAMMARY NEOPLASMS, ANIMAL; METABOLISM; MOUSE; SECONDARY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MORPHOGENETIC PROTEINS; FEMALE; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; LYMPHATIC VESSELS; MACROPHAGES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84938152098     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.189     Document Type: Article

References (59)

1. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51.
2. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-241.
3. Goto K, Kamiya Y, Imamura T, Miyazono K, Miyazawa K. Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. J Biol Chem 2007; 282: 20603-20611.
4. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001; 28: 184-187.
5. Calva-Cerqueira D, Dahdaleh FS, Woodfield G, Chinnathambi S, Nagy PL, Larsen-Haidle J et al. Discovery of the BMPR1A promoter and germline mutations that cause juvenile polyposis. Hum Mol Genet 2010; 19: 4654-4662.
6. Ming Kwan K, Li AG, Wang XJ, Wurst W, Behringer RR. Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis. Genesis 2004; 39: 10-25.
7. Andl T, Ahn K, Kairo A, Chu EY, Wine-Lee L, Reddy ST et al. Epithelial Bmpr1a regulates differentiation and proliferation in postnatal hair follicles and is essential for tooth development. Development 2004; 131: 2257-2268.
8. Kobielak K, Pasolli HA, Alonso L, Polak L, Fuchs E. Defining BMP functions in the hair follicle by conditional ablation of BMP receptor IA. J Cell Biol 2003; 163: 609-623.
9. Yuhki M, Yamada M, Kawano M, Iwasato T, Itohara S, Yoshida H et al. BMPR1A signaling is necessary for hair follicle cycling and hair shaft differentiation in mice. Development 2004; 131: 1825-1833.
10. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012; 150: 764-779.
11. Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME et al. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci USA 2012; 109: 2814-2819.
12. Alarmo EL, Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer 2010; 17: R123-R139.
13. Ehata S, Yokoyama Y, Takahashi K, Miyazono K. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde? Pathol Int 2013; 63: 287-296.
14. Ketolainen JM, Alarmo EL, Tuominen VJ, Kallioniemi A. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat 2010; 124: 377-386.
15. Alarmo EL, Parssinen J, Ketolainen JM, Savinainen K, Karhu R, Kallioniemi A. BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 2009; 275: 35-43.
16. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145: 926-940.
17. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007; 67: 8742-8751.
18. Yang S, Pham LK, Liao CP, Frenkel B, Reddi AH, Roy-Burman P. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer. Cancer Res 2008; 68: 198-205.
19. Owens P, Polikowsky H, Pickup MW, Gorska AE, Jovanovic B, Shaw AK et al. Bone morphogenetic proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion. PLoS ONE 2013; 8: e67533.
20. Wiley DM, Kim JD, Hao J, Hong CC, Bautch VL, Jin SW. Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. Nat Cell Biol 2011; 13: 686-692.
21. Lee JH, Lee GT, Woo SH, Ha YS, Kwon SJ, Kim WJ et al. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res 2013; 73: 3604-3614.
22. Lee GT, Jung YS, Lee JH, Kim WJ, Kim IY. Bone morphogenetic protein 6-induced interleukin-1beta expression in macrophages requires PU.1/Smad1 interaction. Mol Immunol 2011; 48: 1540-1547.
23. Lee GT, Kwon SJ, Lee JH, Jeon SS, Jang KT, Choi HY et al. Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. J Biol Chem 2010; 285: 39401-39408.
24. Hong JH, Lee GT, Lee JH, Kwon SJ, Park SH, Kim SJ et al. Effect of bone morphogenetic protein-6 on macrophages. Immunology 2009; 128: e442-e450.
25. Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 2013; 73: 1020-1030.
26. Langenfeld E, Hong CC, Lanke G, Langenfeld J. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS ONE 2013; 8: e61256.
27. Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 2011; 71: 5194-5203.
28. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR et al. In vivo structureactivity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 2010; 5: 245-253.
29. Hill CR, Sanchez NS, Love JD, Arrieta JA, Hong CC, Brown CB et al. BMP2 signals loss of epithelial character in epicardial cells but requires the Type III TGFbeta receptor to promote invasion. Cell Signal 2012; 24: 1012-1022.
30. Cross EE, Thomason RT, Martinez M, Hopkins CR, Hong CC, Bader DM. Application of small organic molecules reveals cooperative TGFbeta and BMP regulation of mesothelial cell behaviors. ACS Chem Biol 2011; 6: 952-961.
31. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGF-b and BMP pathways. Cell Signal 2011; 23: 1831-1842.
32. Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006; 45: 411-419.
33. Alarmo EL, Kuukasjarvi T, Karhu R, Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 2007; 103: 239-246.
34. Alarmo EL, Korhonen T, Kuukasjarvi T, Huhtala H, Holli K, Kallioniemi A. Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol 2008; 19: 308-314.
35. Alarmo EL, Huhtala H, Korhonen T, Pylkkanen L, Holli K, Kuukasjarvi T et al. Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. Mod Pathol 2013; 26: 10-21.
36. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
37. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
38. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
39. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004; 29: 265-273.
40. Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 2009; 73: 542-563.
41. Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer-a prospect. J Cell Biochem 2007; 101: 1338-1354.
42. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012; 12: 540-552.
43. Hollosi P, Yakushiji JK, Fong KS, Csiszar K, Fong SF. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Int J Cancer 2009; 125: 318-327.
44. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013; 73: 1721-1732.
45. Chen JC, Chang YW, Hong CC, Yu YH, Su JL. The Role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int J Mol Sci 2012; 14: 88-107.
46. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007; 96: 541-545.
47. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 2011; 55: 861-867.
48. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 2004; 36: 1117-1121.
49. Nishimori H, Ehata S, Suzuki HI, Katsuno Y, Miyazono K. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J Biol Chem 2012; 287: 20037-20046.
50. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008; 27: 6322-6333.
51. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 2010; 12: 192-205.
52. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005; 65: 8274-8285.
53. Rodriguez-Martinez A, Alarmo EL, Saarinen L, Ketolainen J, Nousiainen K, Hautaniemi S et al. Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. BMC Med Genomics 2011; 4: 80.
54. Kwon SJ, Lee GT, Lee JH, Kim WJ, Kim IY. Bone morphogenetic protein-6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 2009; 128: e758-e765.
55. Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta deficient mouse mammary carcinoma. Cancer Res 2013; 73: 5336-5346.
56. Owens P, Engelking E, Han G, Haeger SM, Wang XJ. Epidermal Smad4 deletion results in aberrant wound healing. Am J Pathol 2010; 176: 122-133.
57. Novitskiy SV, Pickup MW, Chytil A, Polosukhina D, Owens P, Moses HL. Deletion of TGF-beta signaling in myeloid cells enhances their anti-tumorigenic properties. J Leukoc Biol 2012; 92: 641-651.
58. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M et al. TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov 2011; 1: 430-441.
59. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.